CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Nestlé Health Science›
Analysis
Nestlé Health Science

Nestlé Health Science

Part ofNestlé

Nestlé Health Science makes clinically validated medical nutrition and consumer supplements for patients, caregivers, and everyday consumers.

Operating headquarters
Vevey, canton Vaud, CH🇨🇭
Founded
2011
Loading
Overview
M & A
Relationships
Analysis
Compare
Employees
News
Library

Contents

  1. 01Market Outlook
  2. 02Competitive Strengths
  3. 03Competitive Risks
  1. 01Market Outlook
  2. 02Competitive Strengths
  3. 03Competitive Risks

Market Outlook

The category’s move toward weight management and gut health favors a business that already sells both clinical nutrition and everyday supplements, which is where Nestlé Health Science sits relative to named alternatives Danone (Nutricia), Abbott Nutrition, Herbalife and GNC. Demand for nutrition that supports medical treatment and weight management strengthens that position more than it erodes it.

Two moves put the company directly on the demand shifts reshaping the category: a GLP-1 nutrition support platform launched in 2024 and a longitudinal lifestyle and gut-health study announced in January 2026. Consolidation is also reshaping the business from inside Nestlé, where a 1 April 2026 merger with Nestlé Nutrition concentrated clinical and consumer nutrition lines in one unit.

Source: nutritioninsight.com

Competitive Advantages

Nestlé Health Science’s defensible advantages over named alternatives such as Danone (Nutricia) and Abbott Nutrition in medical nutrition and Herbalife and GNC in supplements rest on holding both a clinically validated medical nutrition line and a retail supplement portfolio in one business. Its products reach more than 140 countries through healthcare professionals, hospitals and pharmacies as well as through retail.

The advantage rests on owned capacity and an acquired brand stable rather than on any single product: eighteen factories and Product Technology Centers in Europe, China and the USA underpin that reach, and the 2021 purchase of The Bountiful Company’s supplement brands and the 2022 Orgain majority stake brought retail brands such as SOLGAR, BOOST and VITAL PROTEINS into the same house as PEPTAMEN, VITAFLO and ISOSOURCE. A GLP-1 nutrition support platform launched in 2024 and a lifestyle and gut-health study announced in January 2026 keep the portfolio sold on clinical evidence.

Source: nestlehealthscience.com

Competitive Disadvantages

Nestlé Health Science’s most exposed flank is medical-nutrition supply, the ground on which Danone (Nutricia) and Abbott Nutrition compete for hospital and pharmacy accounts, and where a withdrawal costs more than anywhere else. Its consumer side, built by acquiring VITAL PROTEINS, SOLGAR, BOOST and related brands, still competes with Herbalife and GNC for retail shelf space.

The withdrawal of enteral products in 2023 shows what that exposure costs: several products were discontinued on cited supply-chain issues and increased demand, with customers routed to alternative products through their Nestlé representative or distributor. Each formula dropped gives up a hospital or pharmacy listing to a competitor that can still fill the order.

Source: policycommons.net